Search Results

You are looking at 1 - 10 of 18 items for :

  • "Dermatologic toxicities" x
Clear All
Full access

Mario E. Lacouture

Oncology providers should take an early, proactive approach in managing dermatologic toxicities associated with cancer treatment, Mario E. Lacouture, MD, emphasized at the NCCN 20th Annual Conference. These toxicities—which affect the skin, hair

Full access

Barbara Burtness

. In closing, prophylactic treatment of dermatologic toxicity associated with targeted therapy may be helpful in delaying the development of grade 2 or higher skin rash. However, Dr. Burtness explained that patients would respond to these same agents if

Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke and Sandy Srinivas

ribosomal protein S6 kinase have been implicated as possible causes of cardiac failure, with hypertension and hypothyroidism as contributing factors. 117 Dermatologic Toxicities: Dermatologic toxicities occur commonly with sorafenib and sunitinib but are

Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz and Sharon Spencer

with anti-epidermal growth factor receptor therapy: survey results . Oncology 2007 ; 72 : 152 – 159 . 28 Wagner LI Lacouture ME . Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist’s perspective. Impact on

Full access

Emily H. Castellanos, Sheau-chiann Chen, Hillary Drexler and Leora Horn

had a stronger negative impact on patient willingness to undergo treatment, compared with dermatologic toxicity ( P <.0001; OR for gastrointestinal vs dermatologic, 0.58; 95% CI, 0.53–0.68; OR for constitutional vs dermatologic, 0.86; 95% CI, 0

Full access

John A. Thompson

Toxicity Maculopapular rash, which can be severe, is one of the more common toxicities seen with ICI therapy. Other dermatologic toxicities can include pruritus, bullous dermatoses, vasculitis, and vitiligo. Management of dermatologic and other AEs is

Full access

681 681 0130679 10.6004/jnccn.2015.0202 Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer Grothey Axel MD 5 2015 13 13 5S 5S 682 682 685 685 0130682 10.6004/jnccn.2015.0203 Management of Dermatologic Toxicities

Full access

.2014.0190 Optimal Treatment of Unresectable Nonmelanoma Skin Cancers Olencki Thomas DO 05 2014 12 12 5S 5S 789 789 792 792 0120789 10.6004/jnccn.2014.0191 Targeted Agents: Management of Dermatologic Toxicities Burtness Barbara MD 05

Full access

Optimal Treatment of Unresectable Nonmelanoma Skin Cancers Targeted Agents: Management of Dermatologic Toxicities Supporters: Breast Cancer Supported by educational grants from AstraZeneca; Eisai Inc.; Genentech; and Novartis Oncology

Full access

John A. Thompson

a 37% reduction in risk of death ( P =.023) with dabrafenib plus trametinib compared with dabrafenib alone in patients with unresectable stage IIIC or IV, BRAF V600E/K mutant melanoma. 10 Dermatologic toxicities are also reduced with the